• Executive Q&A - Early Drug Development

    In this Q&A, we explore early-stage pharmaceutical drug development trends, key scientific and technical challenges, and the role emerging technologies play in enhancing efficiency and quality during early pharmaceutical development. read more
  • Quality: The Gold Standard for CDMOs - No Exceptions, No Compromises

    In today’s hyper-competitive pharmaceutical landscape, innovation, speed-to-market and cost control usually take the spotlight when selecting a contract development and manufacturing organization (CDMO). However, underneath all those metrics, a single truth remains: if quality fails, so does everything else. read more
  • Future-Proofing Pharmacovigilance in an AI Era

    Clinical research organizations (CROs) are entering an era in which pharmacovigilance systems are doing more than just tracking copious amounts of data. They must also keep pace with evolving regulations, manage the growing volume of adverse event reports, and respond to heightened scrutiny from both regulators and the public. read more
  • Why Pharma AI Projects Fail: The Human Problem Behind Technical Success

    Artificial intelligence (AI) is one of the most talked-about tools in the pharmaceutical world, not because of hype, but because of its practical potential. But repeatedly, promising projects stall - or outright fail - not because the models are wrong or the data is flawed, but because people simply don’t use the tools. read more